Avidity's del-brax BLA plan hinges on FORTITUDE biomarker data, not this OLE trial
The planned H2 2026 accelerated-approval filing for del-brax in FSHD rests on the FORTITUDE biomarker cohort readout, while the safety-focused extension study now runs to 2030.
Executive Summary
- Avidity has confirmed with the FDA that an accelerated-approval pathway is open for its DUX4-directed therapy in facioscapulohumeral muscular dystrophy, a disease with no approved treatment, and plans to file for that approval based on a surrogate biomarker rather than a clinical outcome.
- The registered trial tied to this catalyst is an open-label extension focused on long-term treatment-emergent adverse events, not the biomarker data the filing depends on, and its own completion date has moved out by two years.
- The accelerated-approval pathway carries a mandatory confirmatory trial obligation, and Avidity has already started that global Phase 3 study, meaning the BLA submission is one step in a longer approval sequence rather than a stand-alone catalyst.
- No other program targets the same disease-causing gene in clinical testing for this disorder, leaving del-brax without a direct mechanistic comparator even as several differently mechanized programs pursue the same indication.
The regulatory pathway
Avidity announced on June 9, 2025 that the FDA confirmed the accelerated-approval pathway is open in the United States for del-brax, an antibody oligonucleotide conjugate designed to act on the DUX4 gene believed to drive FSHD. The FDA gave Avidity detailed direction on the validation steps required for the surrogate biomarker that would support that pathway, since accelerated approval requires a marker considered likely, but not proven, to predict clinical benefit. Sarah Boyce, Avidity's president and chief executive officer, said the company had "confirmed with the FDA that the accelerated approval pathway is open for del-brax". FSHD currently has no approved therapy and affects an estimated 45,000 to 87,000 people across the United States and Europe, according to the same disclosure. AvidityAvidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHDJun 9, 2025
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the filing rests on
The planned BLA submission is timed to follow topline data from the FORTITUDE biomarker cohort, expected in the first half of 2026, not the trial the catalyst is registered against, NCT06547216. That trial, called FORTITUDE-OLE, is a Phase 2 open-label extension whose sole registered primary endpoint is the incidence of treatment-emergent adverse events, a safety measure rather than the efficacy or biomarker signal a filing would need. No results have posted on the registry for that trial as of this writing, and its primary completion date moved from April 2028 to April 2030, a 24-month shift recorded alongside a status change from Enrolling by Invitation to Active, not recruiting in May 2026. NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)NCT06547216
The confirmatory requirement
Accelerated approval under this pathway carries a mandatory confirmatory trial obligation, and Avidity has already started that study: a global, placebo-controlled, double-blind Phase 3 trial called FORWARD, designed to run 18 months in roughly 200 patients across North America, Europe and Japan, with Quantitative Muscle Testing currently assigned as the primary endpoint. The design keeps flexibility to elevate other functional measures, including 10-meter walk/run time and Timed Up and Go, or patient-reported outcomes to primary status as more FORTITUDE biomarker data accumulate. That confirmatory obligation means a BLA filing, even if accepted, does not close the regulatory question; it opens a multi-year period in which withdrawal risk exists if the Phase 3 study does not confirm clinical benefit. AvidityAvidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHDJun 9, 2025
The competitive field
No other clinical-stage program targets DUX4 with an approved comparator or resolved trial in FSHD, leaving del-brax without a direct precedent on its own mechanism. Other sponsors are pursuing the indication through different biology: Fulcrum Therapeutics' losmapimod targets p38 MAPK inhibition in a Phase 3 trial, and myostatin-pathway candidates from Scholar Rock and Roche are in Phase 2 testing. None of these mechanistic neighbors has produced an approval or a disclosed positive Phase 3 result in FSHD to date, consistent with a field where no disease-modifying mechanism has yet been validated in this indication.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.